Petter Bjornstad
Concepts (454)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diabetic Nephropathies | 92 | 2026 | 320 | 26.620 |
Why?
| | Diabetes Mellitus, Type 2 | 83 | 2026 | 2623 | 11.580 |
Why?
| | Diabetes Mellitus, Type 1 | 86 | 2026 | 3930 | 10.320 |
Why?
| | Glomerular Filtration Rate | 73 | 2026 | 745 | 9.250 |
Why?
| | Kidney | 60 | 2026 | 1498 | 7.360 |
Why?
| | Insulin Resistance | 25 | 2026 | 1247 | 5.270 |
Why?
| | Renal Insufficiency, Chronic | 30 | 2026 | 640 | 4.920 |
Why?
| | Uric Acid | 23 | 2022 | 167 | 4.370 |
Why?
| | Albuminuria | 24 | 2026 | 190 | 4.160 |
Why?
| | Biomarkers | 42 | 2026 | 4340 | 2.970 |
Why?
| | Sodium-Glucose Transporter 2 | 14 | 2026 | 29 | 2.950 |
Why?
| | Cardiovascular Diseases | 19 | 2026 | 2219 | 2.780 |
Why?
| | Bariatric Surgery | 6 | 2026 | 250 | 2.710 |
Why?
| | Pediatric Obesity | 9 | 2025 | 635 | 2.700 |
Why?
| | Hemodynamics | 23 | 2025 | 1114 | 2.630 |
Why?
| | Metformin | 12 | 2025 | 328 | 2.610 |
Why?
| | Hypoglycemic Agents | 28 | 2026 | 1412 | 2.570 |
Why?
| | Renal Insufficiency | 6 | 2023 | 173 | 2.530 |
Why?
| | Coronary Artery Disease | 11 | 2022 | 751 | 2.360 |
Why?
| | Diabetic Angiopathies | 9 | 2019 | 265 | 2.280 |
Why?
| | Glucosides | 15 | 2026 | 56 | 2.260 |
Why?
| | Benzhydryl Compounds | 15 | 2026 | 81 | 2.210 |
Why?
| | Glycopeptides | 10 | 2021 | 48 | 2.090 |
Why?
| | Adolescent | 71 | 2026 | 22557 | 2.020 |
Why?
| | Vascular Calcification | 6 | 2022 | 109 | 2.010 |
Why?
| | Obesity, Morbid | 5 | 2020 | 287 | 1.950 |
Why?
| | Humans | 203 | 2026 | 146342 | 1.890 |
Why?
| | Renin-Angiotensin System | 10 | 2021 | 80 | 1.820 |
Why?
| | Kidney Diseases | 4 | 2025 | 428 | 1.750 |
Why?
| | Creatinine | 21 | 2026 | 511 | 1.660 |
Why?
| | Disease Progression | 26 | 2026 | 2867 | 1.530 |
Why?
| | Male | 124 | 2026 | 73396 | 1.530 |
Why?
| | Young Adult | 48 | 2026 | 14330 | 1.520 |
Why?
| | Sex Characteristics | 7 | 2025 | 801 | 1.500 |
Why?
| | Female | 119 | 2026 | 79499 | 1.430 |
Why?
| | Glucagon-Like Peptides | 4 | 2026 | 76 | 1.360 |
Why?
| | Diabetic Ketoacidosis | 4 | 2025 | 212 | 1.350 |
Why?
| | Obesity | 15 | 2026 | 3131 | 1.350 |
Why?
| | Calcinosis | 4 | 2015 | 231 | 1.230 |
Why?
| | Blood Glucose | 17 | 2026 | 2360 | 1.220 |
Why?
| | Risk Factors | 40 | 2026 | 10921 | 1.210 |
Why?
| | Adult | 67 | 2026 | 41087 | 1.160 |
Why?
| | Child | 40 | 2026 | 22693 | 1.100 |
Why?
| | Diabetic Cardiomyopathies | 4 | 2020 | 34 | 1.090 |
Why?
| | Mechanistic Target of Rapamycin Complex 1 | 2 | 2026 | 141 | 1.050 |
Why?
| | Follow-Up Studies | 22 | 2026 | 5439 | 1.020 |
Why?
| | Adiposity | 6 | 2025 | 533 | 1.010 |
Why?
| | Hyperglycemia | 6 | 2025 | 384 | 0.990 |
Why?
| | Kidney Glomerulus | 7 | 2026 | 129 | 0.960 |
Why?
| | Middle Aged | 65 | 2026 | 36619 | 0.950 |
Why?
| | Hypertension | 9 | 2021 | 1272 | 0.940 |
Why?
| | Cardio-Renal Syndrome | 1 | 2026 | 20 | 0.940 |
Why?
| | Janus Kinases | 1 | 2026 | 21 | 0.920 |
Why?
| | STAT Transcription Factors | 1 | 2026 | 25 | 0.920 |
Why?
| | Prognosis | 17 | 2026 | 4351 | 0.920 |
Why?
| | Arterioles | 3 | 2024 | 52 | 0.910 |
Why?
| | Proteinuria | 3 | 2026 | 103 | 0.910 |
Why?
| | Acute Kidney Injury | 6 | 2025 | 866 | 0.900 |
Why?
| | Atherosclerosis | 4 | 2018 | 410 | 0.900 |
Why?
| | Body Composition | 4 | 2026 | 689 | 0.900 |
Why?
| | Exercise Tolerance | 3 | 2017 | 289 | 0.880 |
Why?
| | Vascular Stiffness | 7 | 2022 | 488 | 0.870 |
Why?
| | Fructose | 4 | 2021 | 132 | 0.870 |
Why?
| | Apolipoproteins B | 2 | 2015 | 48 | 0.870 |
Why?
| | Uromodulin | 3 | 2019 | 22 | 0.850 |
Why?
| | Hyperuricemia | 6 | 2021 | 47 | 0.840 |
Why?
| | Vasopressins | 3 | 2023 | 60 | 0.830 |
Why?
| | Iohexol | 3 | 2025 | 23 | 0.830 |
Why?
| | Adiponectin | 2 | 2016 | 243 | 0.820 |
Why?
| | Immunoglobulin Fc Fragments | 1 | 2024 | 41 | 0.820 |
Why?
| | Cross-Sectional Studies | 19 | 2025 | 5899 | 0.820 |
Why?
| | Case-Control Studies | 14 | 2025 | 3647 | 0.820 |
Why?
| | Iothalamic Acid | 1 | 2022 | 5 | 0.750 |
Why?
| | Kidney Tubules | 2 | 2021 | 117 | 0.750 |
Why?
| | Dyslipidemias | 5 | 2021 | 184 | 0.740 |
Why?
| | Kidney Failure, Chronic | 5 | 2026 | 589 | 0.740 |
Why?
| | Blood Pressure | 10 | 2025 | 1765 | 0.740 |
Why?
| | Diabetic Retinopathy | 4 | 2021 | 211 | 0.730 |
Why?
| | Prediabetic State | 1 | 2025 | 250 | 0.720 |
Why?
| | Cystatin C | 8 | 2023 | 65 | 0.720 |
Why?
| | Epithelial-Mesenchymal Transition | 1 | 2024 | 219 | 0.710 |
Why?
| | Epidermal Growth Factor | 4 | 2026 | 157 | 0.710 |
Why?
| | Hyperoxia | 1 | 2024 | 126 | 0.710 |
Why?
| | Recombinant Fusion Proteins | 1 | 2024 | 663 | 0.680 |
Why?
| | Bone Density | 1 | 2025 | 494 | 0.660 |
Why?
| | Polycystic Kidney, Autosomal Dominant | 1 | 2024 | 244 | 0.640 |
Why?
| | Podocytes | 3 | 2026 | 80 | 0.620 |
Why?
| | Kidney Function Tests | 7 | 2026 | 156 | 0.620 |
Why?
| | Fasting | 3 | 2026 | 280 | 0.620 |
Why?
| | Oxygen Consumption | 3 | 2017 | 721 | 0.610 |
Why?
| | Triglycerides | 3 | 2022 | 527 | 0.600 |
Why?
| | Insulin | 11 | 2026 | 2525 | 0.590 |
Why?
| | Pilot Projects | 8 | 2026 | 1888 | 0.590 |
Why?
| | Vascular Resistance | 6 | 2020 | 365 | 0.590 |
Why?
| | Mitochondria | 1 | 2026 | 997 | 0.590 |
Why?
| | Dried Blood Spot Testing | 2 | 2018 | 129 | 0.580 |
Why?
| | Endothelial Cells | 4 | 2026 | 876 | 0.580 |
Why?
| | Cyclic GMP | 1 | 2019 | 88 | 0.580 |
Why?
| | Incidence | 11 | 2026 | 2936 | 0.580 |
Why?
| | Oxygen | 2 | 2024 | 997 | 0.570 |
Why?
| | Lipid Metabolism Disorders | 1 | 2018 | 4 | 0.570 |
Why?
| | Coronary Vessels | 3 | 2017 | 245 | 0.560 |
Why?
| | Longevity | 6 | 2022 | 179 | 0.560 |
Why?
| | Aged | 40 | 2026 | 26432 | 0.560 |
Why?
| | Cardiotonic Agents | 1 | 2018 | 96 | 0.550 |
Why?
| | Gastric Bypass | 1 | 2020 | 115 | 0.550 |
Why?
| | Leptin | 2 | 2017 | 248 | 0.540 |
Why?
| | Cohort Studies | 18 | 2025 | 6077 | 0.540 |
Why?
| | Hemofiltration | 1 | 2018 | 24 | 0.540 |
Why?
| | Weight Reduction Programs | 1 | 2019 | 140 | 0.530 |
Why?
| | Overweight | 3 | 2025 | 614 | 0.530 |
Why?
| | Sodium Bicarbonate | 1 | 2018 | 48 | 0.530 |
Why?
| | Cholesterol, HDL | 2 | 2015 | 201 | 0.520 |
Why?
| | Blood Vessels | 1 | 2018 | 164 | 0.510 |
Why?
| | Ventricular Function, Left | 3 | 2020 | 541 | 0.510 |
Why?
| | Glucose | 5 | 2023 | 1053 | 0.510 |
Why?
| | Inflammation | 3 | 2026 | 2919 | 0.490 |
Why?
| | Canagliflozin | 4 | 2026 | 11 | 0.490 |
Why?
| | Aorta | 2 | 2019 | 440 | 0.480 |
Why?
| | Up-Regulation | 2 | 2016 | 841 | 0.480 |
Why?
| | Nutrition Surveys | 1 | 2017 | 270 | 0.470 |
Why?
| | Cholesterol, LDL | 2 | 2014 | 363 | 0.460 |
Why?
| | Testosterone | 4 | 2026 | 419 | 0.460 |
Why?
| | Glucose Clamp Technique | 7 | 2026 | 199 | 0.450 |
Why?
| | Body Mass Index | 10 | 2026 | 2458 | 0.440 |
Why?
| | Drug Therapy, Combination | 6 | 2025 | 1036 | 0.430 |
Why?
| | Renal Circulation | 3 | 2021 | 75 | 0.430 |
Why?
| | Angiotensin II Type 2 Receptor Blockers | 1 | 2014 | 7 | 0.420 |
Why?
| | Canada | 7 | 2022 | 432 | 0.420 |
Why?
| | Nephrotic Syndrome | 2 | 2026 | 44 | 0.410 |
Why?
| | Sodium | 5 | 2025 | 196 | 0.410 |
Why?
| | Gastrectomy | 2 | 2026 | 164 | 0.400 |
Why?
| | Natriuresis | 3 | 2025 | 13 | 0.400 |
Why?
| | Signal Transduction | 3 | 2026 | 5246 | 0.400 |
Why?
| | Echocardiography | 2 | 2018 | 645 | 0.400 |
Why?
| | Pregnancy Outcome | 1 | 2017 | 503 | 0.400 |
Why?
| | Dietary Supplements | 1 | 2018 | 587 | 0.390 |
Why?
| | Hypoxia | 2 | 2020 | 1211 | 0.390 |
Why?
| | Estradiol | 3 | 2026 | 517 | 0.390 |
Why?
| | Goals | 1 | 2015 | 187 | 0.380 |
Why?
| | Vasoconstriction | 3 | 2020 | 216 | 0.380 |
Why?
| | Patient Care Planning | 1 | 2014 | 170 | 0.370 |
Why?
| | Glucagon-Like Peptide 1 | 5 | 2026 | 150 | 0.370 |
Why?
| | Chitinase-3-Like Protein 1 | 2 | 2022 | 18 | 0.370 |
Why?
| | Brain | 1 | 2025 | 2991 | 0.360 |
Why?
| | Heart Failure | 3 | 2021 | 2329 | 0.360 |
Why?
| | Clinical Trials as Topic | 7 | 2025 | 1064 | 0.360 |
Why?
| | Histidine | 2 | 2022 | 67 | 0.350 |
Why?
| | Contrast Media | 1 | 2015 | 493 | 0.350 |
Why?
| | Double-Blind Method | 7 | 2026 | 2070 | 0.350 |
Why?
| | Age of Onset | 2 | 2025 | 558 | 0.340 |
Why?
| | Prospective Studies | 11 | 2026 | 8123 | 0.340 |
Why?
| | Lipids | 2 | 2022 | 714 | 0.330 |
Why?
| | Proteome | 2 | 2026 | 520 | 0.330 |
Why?
| | Albumins | 3 | 2022 | 120 | 0.330 |
Why?
| | Angiotensin II | 3 | 2020 | 102 | 0.320 |
Why?
| | Guideline Adherence | 1 | 2015 | 594 | 0.310 |
Why?
| | Absorptiometry, Photon | 2 | 2025 | 278 | 0.310 |
Why?
| | Lipocalin-2 | 2 | 2022 | 80 | 0.310 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2014 | 449 | 0.310 |
Why?
| | Precision Medicine | 2 | 2026 | 462 | 0.290 |
Why?
| | Animals | 19 | 2026 | 38106 | 0.290 |
Why?
| | Energy Metabolism | 2 | 2026 | 930 | 0.290 |
Why?
| | Linagliptin | 2 | 2026 | 5 | 0.280 |
Why?
| | Pulse Wave Analysis | 5 | 2022 | 268 | 0.280 |
Why?
| | Running | 2 | 2023 | 235 | 0.280 |
Why?
| | Biopsy | 4 | 2026 | 1075 | 0.270 |
Why?
| | Treatment Outcome | 12 | 2026 | 11821 | 0.270 |
Why?
| | Diabetes Complications | 2 | 2021 | 219 | 0.260 |
Why?
| | Magnetic Resonance Imaging | 6 | 2025 | 3926 | 0.250 |
Why?
| | Metabolic Syndrome | 3 | 2021 | 364 | 0.250 |
Why?
| | Time Factors | 7 | 2025 | 7109 | 0.250 |
Why?
| | Clusterin | 1 | 2026 | 11 | 0.240 |
Why?
| | Sex Factors | 5 | 2025 | 2107 | 0.240 |
Why?
| | Dipeptidyl-Peptidase IV Inhibitors | 3 | 2025 | 46 | 0.240 |
Why?
| | Randomized Controlled Trials as Topic | 5 | 2026 | 1763 | 0.240 |
Why?
| | MEF2 Transcription Factors | 1 | 2026 | 51 | 0.240 |
Why?
| | Diet, Carbohydrate-Restricted | 1 | 2026 | 36 | 0.240 |
Why?
| | Heat Stress Disorders | 2 | 2018 | 84 | 0.240 |
Why?
| | Glucagon-Like Peptide-1 Receptor | 3 | 2021 | 88 | 0.230 |
Why?
| | Age Factors | 7 | 2019 | 3347 | 0.230 |
Why?
| | Severity of Illness Index | 3 | 2021 | 2921 | 0.230 |
Why?
| | Diabetes Mellitus | 3 | 2021 | 1101 | 0.230 |
Why?
| | Hydrogen-Ion Concentration | 2 | 2018 | 533 | 0.220 |
Why?
| | Gliclazide | 1 | 2025 | 2 | 0.220 |
Why?
| | Colorado | 4 | 2017 | 4595 | 0.220 |
Why?
| | Abdominal Fat | 1 | 2025 | 51 | 0.220 |
Why?
| | Osmolar Concentration | 3 | 2026 | 165 | 0.220 |
Why?
| | Leucine | 2 | 2024 | 116 | 0.220 |
Why?
| | Fatty Acid Binding Protein 3 | 1 | 2024 | 6 | 0.220 |
Why?
| | Early Diagnosis | 2 | 2017 | 251 | 0.210 |
Why?
| | Vascular Cell Adhesion Molecule-1 | 1 | 2024 | 42 | 0.210 |
Why?
| | Predictive Value of Tests | 4 | 2018 | 2113 | 0.210 |
Why?
| | Citric Acid Cycle | 1 | 2024 | 58 | 0.210 |
Why?
| | Renin | 2 | 2022 | 33 | 0.210 |
Why?
| | Diuretics | 2 | 2023 | 66 | 0.210 |
Why?
| | Androgen Antagonists | 1 | 2025 | 91 | 0.210 |
Why?
| | Gray Matter | 1 | 2025 | 96 | 0.210 |
Why?
| | Lipoproteins | 2 | 2022 | 165 | 0.210 |
Why?
| | Endothelin Receptor Antagonists | 2 | 2024 | 60 | 0.200 |
Why?
| | Blood Proteins | 1 | 2026 | 239 | 0.200 |
Why?
| | Consensus | 2 | 2022 | 467 | 0.200 |
Why?
| | Gonadal Steroid Hormones | 1 | 2024 | 143 | 0.190 |
Why?
| | Receptors, Vasopressin | 2 | 2021 | 20 | 0.190 |
Why?
| | Mineralocorticoid Receptor Antagonists | 2 | 2024 | 69 | 0.190 |
Why?
| | Extracellular Vesicles | 1 | 2026 | 176 | 0.190 |
Why?
| | Inappropriate ADH Syndrome | 1 | 2023 | 7 | 0.190 |
Why?
| | Nephrosis, Lipoid | 1 | 2023 | 11 | 0.190 |
Why?
| | National Institutes of Health (U.S.) | 1 | 2024 | 147 | 0.190 |
Why?
| | Cysts | 1 | 2024 | 108 | 0.190 |
Why?
| | Membrane Glycoproteins | 1 | 2026 | 495 | 0.190 |
Why?
| | Fluorocarbons | 1 | 2024 | 122 | 0.190 |
Why?
| | Pancreas | 1 | 2025 | 343 | 0.190 |
Why?
| | Hyponatremia | 1 | 2023 | 42 | 0.190 |
Why?
| | Single-Cell Analysis | 1 | 2026 | 370 | 0.180 |
Why?
| | Transcriptome | 2 | 2026 | 1068 | 0.180 |
Why?
| | Malates | 1 | 2022 | 8 | 0.180 |
Why?
| | Fumarates | 1 | 2022 | 10 | 0.180 |
Why?
| | Threonine | 1 | 2022 | 43 | 0.180 |
Why?
| | Iodine Radioisotopes | 1 | 2022 | 139 | 0.180 |
Why?
| | Longitudinal Studies | 5 | 2024 | 3017 | 0.180 |
Why?
| | Carboxylic Acids | 1 | 2022 | 32 | 0.180 |
Why?
| | Diabetes Mellitus, Experimental | 1 | 2023 | 198 | 0.180 |
Why?
| | Pathology, Clinical | 1 | 2022 | 29 | 0.180 |
Why?
| | Phenylalanine | 1 | 2022 | 69 | 0.170 |
Why?
| | Rats | 2 | 2024 | 5586 | 0.170 |
Why?
| | Heart | 1 | 2025 | 626 | 0.170 |
Why?
| | Amino Acids | 2 | 2024 | 515 | 0.170 |
Why?
| | Patient Participation | 1 | 2025 | 457 | 0.170 |
Why?
| | Chemokine CCL2 | 1 | 2022 | 112 | 0.170 |
Why?
| | Arizona | 1 | 2021 | 81 | 0.170 |
Why?
| | Health Status Disparities | 1 | 2024 | 322 | 0.170 |
Why?
| | Weight Loss | 3 | 2026 | 858 | 0.170 |
Why?
| | Glycine | 1 | 2022 | 184 | 0.160 |
Why?
| | Risk Assessment | 6 | 2026 | 3712 | 0.160 |
Why?
| | Mice | 7 | 2026 | 18297 | 0.160 |
Why?
| | Oxidation-Reduction | 1 | 2024 | 1075 | 0.160 |
Why?
| | p-Aminohippuric Acid | 1 | 2020 | 5 | 0.160 |
Why?
| | Image Processing, Computer-Assisted | 1 | 2025 | 778 | 0.160 |
Why?
| | Tryptophan | 1 | 2022 | 184 | 0.160 |
Why?
| | Interleukin-18 | 1 | 2022 | 234 | 0.160 |
Why?
| | Multivariate Analysis | 2 | 2014 | 1543 | 0.160 |
Why?
| | Nephrosis | 1 | 2020 | 6 | 0.160 |
Why?
| | Furosemide | 1 | 2020 | 37 | 0.160 |
Why?
| | Natriuretic Peptide, Brain | 1 | 2021 | 110 | 0.160 |
Why?
| | Asymptomatic Diseases | 2 | 2019 | 102 | 0.160 |
Why?
| | Japan | 5 | 2017 | 149 | 0.160 |
Why?
| | Clinical Trials, Phase III as Topic | 3 | 2025 | 116 | 0.150 |
Why?
| | Angiotensin-Converting Enzyme Inhibitors | 2 | 2024 | 228 | 0.150 |
Why?
| | Diabetic Neuropathies | 1 | 2021 | 101 | 0.150 |
Why?
| | Machine Learning | 1 | 2026 | 594 | 0.150 |
Why?
| | Calcium Channel Blockers | 1 | 2021 | 165 | 0.150 |
Why?
| | Sodium-Glucose Transporter 1 | 1 | 2019 | 11 | 0.150 |
Why?
| | Transgender Persons | 1 | 2023 | 213 | 0.150 |
Why?
| | Body Water | 1 | 2019 | 23 | 0.150 |
Why?
| | Diabetic Foot | 1 | 2019 | 25 | 0.150 |
Why?
| | Models, Biological | 3 | 2016 | 1761 | 0.150 |
Why?
| | Oxidative Stress | 1 | 2026 | 1369 | 0.150 |
Why?
| | Glycolysis | 1 | 2021 | 342 | 0.150 |
Why?
| | Multicenter Studies as Topic | 3 | 2025 | 417 | 0.150 |
Why?
| | Glomerulonephritis | 1 | 2019 | 46 | 0.150 |
Why?
| | Glycosides | 1 | 2019 | 43 | 0.140 |
Why?
| | Blood Chemical Analysis | 1 | 2019 | 109 | 0.140 |
Why?
| | Postmenopause | 1 | 2021 | 394 | 0.140 |
Why?
| | beta 2-Microglobulin | 1 | 2018 | 47 | 0.140 |
Why?
| | Software | 2 | 2025 | 676 | 0.140 |
Why?
| | Myocardial Contraction | 1 | 2020 | 292 | 0.140 |
Why?
| | Proof of Concept Study | 3 | 2025 | 90 | 0.140 |
Why?
| | Carotid Intima-Media Thickness | 1 | 2018 | 75 | 0.140 |
Why?
| | Cell Proliferation | 1 | 2026 | 2502 | 0.140 |
Why?
| | Body Temperature Regulation | 1 | 2019 | 106 | 0.140 |
Why?
| | Microscopy, Polarization | 1 | 2018 | 30 | 0.140 |
Why?
| | Pharmaceutical Preparations | 1 | 2020 | 172 | 0.140 |
Why?
| | Hepatitis A Virus Cellular Receptor 1 | 1 | 2018 | 42 | 0.130 |
Why?
| | Allopurinol | 1 | 2018 | 70 | 0.130 |
Why?
| | Obesity, Metabolically Benign | 1 | 2017 | 4 | 0.130 |
Why?
| | Child, Preschool | 4 | 2025 | 11913 | 0.130 |
Why?
| | Prehypertension | 1 | 2017 | 27 | 0.130 |
Why?
| | Glucose Tolerance Test | 2 | 2019 | 360 | 0.130 |
Why?
| | Glomerulosclerosis, Focal Segmental | 1 | 2017 | 43 | 0.130 |
Why?
| | Hyperthermia, Induced | 1 | 2018 | 119 | 0.120 |
Why?
| | Urinary Calculi | 1 | 2017 | 10 | 0.120 |
Why?
| | Deamino Arginine Vasopressin | 1 | 2016 | 15 | 0.120 |
Why?
| | Peptide Fragments | 1 | 2021 | 693 | 0.120 |
Why?
| | Ventricular Dysfunction, Left | 1 | 2020 | 391 | 0.120 |
Why?
| | Life Style | 1 | 2019 | 496 | 0.120 |
Why?
| | Magnetic Resonance Angiography | 1 | 2018 | 249 | 0.120 |
Why?
| | Morbidity | 1 | 2017 | 319 | 0.120 |
Why?
| | Blood Banks | 1 | 2016 | 50 | 0.120 |
Why?
| | Dehydration | 1 | 2016 | 59 | 0.120 |
Why?
| | Regional Blood Flow | 1 | 2018 | 507 | 0.120 |
Why?
| | Vasodilation | 1 | 2020 | 519 | 0.120 |
Why?
| | Cardiorespiratory Fitness | 1 | 2017 | 73 | 0.120 |
Why?
| | Gastrointestinal Microbiome | 1 | 2024 | 769 | 0.120 |
Why?
| | Anti-Inflammatory Agents | 1 | 2020 | 474 | 0.120 |
Why?
| | Tomography, X-Ray Computed | 2 | 2018 | 2786 | 0.120 |
Why?
| | Disease Models, Animal | 5 | 2021 | 4580 | 0.120 |
Why?
| | Vitreoretinopathy, Proliferative | 1 | 2016 | 15 | 0.120 |
Why?
| | Linear Models | 2 | 2017 | 857 | 0.120 |
Why?
| | Logistic Models | 3 | 2017 | 2126 | 0.120 |
Why?
| | Survival Rate | 2 | 2017 | 2092 | 0.110 |
Why?
| | Heart Rate | 1 | 2019 | 846 | 0.110 |
Why?
| | Cognition | 1 | 2024 | 1292 | 0.110 |
Why?
| | Echocardiography, Doppler | 1 | 2016 | 117 | 0.110 |
Why?
| | Hot Temperature | 1 | 2018 | 396 | 0.110 |
Why?
| | Gene Expression Regulation | 2 | 2026 | 2599 | 0.110 |
Why?
| | Filtration | 1 | 2015 | 68 | 0.110 |
Why?
| | Liver Diseases | 1 | 2018 | 304 | 0.110 |
Why?
| | Apolipoproteins | 1 | 2014 | 38 | 0.110 |
Why?
| | Integrin beta1 | 2 | 2026 | 31 | 0.110 |
Why?
| | Enzyme Inhibitors | 1 | 2018 | 823 | 0.100 |
Why?
| | Blood Pressure Determination | 1 | 2015 | 143 | 0.100 |
Why?
| | Purines | 1 | 2015 | 188 | 0.100 |
Why?
| | Phenotype | 1 | 2022 | 3206 | 0.100 |
Why?
| | Achievement | 1 | 2014 | 58 | 0.100 |
Why?
| | Peptides | 3 | 2026 | 992 | 0.100 |
Why?
| | Stress, Mechanical | 1 | 2016 | 497 | 0.100 |
Why?
| | Retrospective Studies | 9 | 2026 | 17438 | 0.100 |
Why?
| | Immunity, Innate | 1 | 2019 | 844 | 0.100 |
Why?
| | Gene Regulatory Networks | 2 | 2026 | 319 | 0.100 |
Why?
| | Liver | 2 | 2021 | 1864 | 0.100 |
Why?
| | Fatty Acids | 2 | 2026 | 460 | 0.090 |
Why?
| | Primary Prevention | 1 | 2015 | 222 | 0.090 |
Why?
| | Exercise Test | 1 | 2016 | 637 | 0.090 |
Why?
| | Research Design | 1 | 2019 | 1143 | 0.090 |
Why?
| | Adenosine Triphosphate | 1 | 2015 | 494 | 0.090 |
Why?
| | Cholesterol | 1 | 2014 | 411 | 0.090 |
Why?
| | Biomechanical Phenomena | 1 | 2016 | 874 | 0.090 |
Why?
| | Cross-Over Studies | 2 | 2026 | 615 | 0.090 |
Why?
| | United States | 3 | 2024 | 16136 | 0.090 |
Why?
| | Antihypertensive Agents | 1 | 2016 | 519 | 0.090 |
Why?
| | Regression Analysis | 1 | 2014 | 999 | 0.090 |
Why?
| | RNA, Messenger | 1 | 2019 | 2791 | 0.080 |
Why?
| | Aged, 80 and over | 3 | 2018 | 8391 | 0.080 |
Why?
| | Vascular Diseases | 1 | 2013 | 252 | 0.080 |
Why?
| | Feasibility Studies | 1 | 2015 | 1135 | 0.080 |
Why?
| | Hematocrit | 2 | 2021 | 108 | 0.080 |
Why?
| | Exercise | 1 | 2022 | 2213 | 0.080 |
Why?
| | Societies, Medical | 1 | 2015 | 907 | 0.080 |
Why?
| | Ambulatory Care | 1 | 2015 | 628 | 0.080 |
Why?
| | Practice Guidelines as Topic | 1 | 2017 | 1591 | 0.070 |
Why?
| | Proteomics | 2 | 2026 | 1203 | 0.070 |
Why?
| | Fructokinases | 2 | 2021 | 42 | 0.070 |
Why?
| | Registries | 1 | 2016 | 2400 | 0.060 |
Why?
| | Prevalence | 3 | 2019 | 2861 | 0.060 |
Why?
| | Reproducibility of Results | 1 | 2015 | 3416 | 0.060 |
Why?
| | Fibrosis | 2 | 2021 | 568 | 0.060 |
Why?
| | Mesangial Cells | 1 | 2026 | 4 | 0.060 |
Why?
| | Clinical Trials, Phase II as Topic | 1 | 2026 | 74 | 0.060 |
Why?
| | Mice, Knockout | 2 | 2026 | 3125 | 0.060 |
Why?
| | Peptide YY | 1 | 2026 | 28 | 0.060 |
Why?
| | Infant | 2 | 2025 | 10114 | 0.060 |
Why?
| | Receptors, Complement | 1 | 2026 | 126 | 0.060 |
Why?
| | Nephrectomy | 1 | 2026 | 172 | 0.050 |
Why?
| | C-Peptide | 1 | 2026 | 191 | 0.050 |
Why?
| | Transforming Growth Factor beta1 | 1 | 2026 | 176 | 0.050 |
Why?
| | Organ Size | 1 | 2025 | 465 | 0.050 |
Why?
| | Living Donors | 1 | 2026 | 216 | 0.050 |
Why?
| | Postprandial Period | 1 | 2025 | 114 | 0.050 |
Why?
| | United Kingdom | 1 | 2025 | 377 | 0.050 |
Why?
| | Isoleucine | 1 | 2024 | 15 | 0.050 |
Why?
| | Propensity Score | 1 | 2026 | 376 | 0.050 |
Why?
| | Pregnancy | 1 | 2017 | 7230 | 0.050 |
Why?
| | Cell Communication | 1 | 2026 | 327 | 0.050 |
Why?
| | Valine | 1 | 2024 | 84 | 0.050 |
Why?
| | Obesity, Abdominal | 1 | 2024 | 48 | 0.050 |
Why?
| | Doxorubicin | 1 | 2026 | 416 | 0.050 |
Why?
| | Mice, Inbred C57BL | 3 | 2021 | 6034 | 0.050 |
Why?
| | Bromocriptine | 1 | 2022 | 31 | 0.050 |
Why?
| | Antibodies | 1 | 2025 | 400 | 0.050 |
Why?
| | Environmental Pollutants | 1 | 2024 | 143 | 0.050 |
Why?
| | Tandem Mass Spectrometry | 1 | 2026 | 576 | 0.050 |
Why?
| | RNA, Transfer | 1 | 2024 | 142 | 0.050 |
Why?
| | Aging | 1 | 2014 | 1996 | 0.050 |
Why?
| | Benzbromarone | 1 | 2022 | 1 | 0.050 |
Why?
| | Cytokines | 2 | 2021 | 2081 | 0.050 |
Why?
| | Infant, Newborn | 1 | 2014 | 6460 | 0.050 |
Why?
| | Aldosterone | 1 | 2022 | 42 | 0.040 |
Why?
| | NF-kappa B | 1 | 2026 | 674 | 0.040 |
Why?
| | Glycoproteins | 1 | 2024 | 356 | 0.040 |
Why?
| | Controlled Clinical Trials as Topic | 1 | 2021 | 26 | 0.040 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2026 | 1224 | 0.040 |
Why?
| | Inulin | 1 | 2021 | 12 | 0.040 |
Why?
| | Adenine | 1 | 2023 | 339 | 0.040 |
Why?
| | Hep G2 Cells | 1 | 2021 | 74 | 0.040 |
Why?
| | Drinking | 1 | 2021 | 44 | 0.040 |
Why?
| | Serum Albumin | 1 | 2021 | 147 | 0.040 |
Why?
| | Uricosuric Agents | 1 | 2020 | 2 | 0.040 |
Why?
| | Insulin Infusion Systems | 1 | 2026 | 488 | 0.040 |
Why?
| | Diuretics, Osmotic | 1 | 2020 | 2 | 0.040 |
Why?
| | Cell Hypoxia | 1 | 2021 | 249 | 0.040 |
Why?
| | Mendelian Randomization Analysis | 1 | 2020 | 68 | 0.040 |
Why?
| | TOR Serine-Threonine Kinases | 1 | 2023 | 455 | 0.040 |
Why?
| | Chemokines | 1 | 2021 | 217 | 0.040 |
Why?
| | Environmental Exposure | 1 | 2024 | 578 | 0.040 |
Why?
| | Diastole | 1 | 2020 | 147 | 0.040 |
Why?
| | Systole | 1 | 2020 | 179 | 0.040 |
Why?
| | Cytoprotection | 1 | 2019 | 55 | 0.040 |
Why?
| | Netherlands | 1 | 2019 | 85 | 0.040 |
Why?
| | Models, Theoretical | 1 | 2023 | 561 | 0.040 |
Why?
| | Recurrence | 1 | 2023 | 1133 | 0.040 |
Why?
| | Lipopolysaccharides | 1 | 2023 | 861 | 0.040 |
Why?
| | Drug Interactions | 1 | 2021 | 405 | 0.040 |
Why?
| | Preoperative Period | 1 | 2019 | 157 | 0.040 |
Why?
| | Neuropsychological Tests | 1 | 2024 | 1149 | 0.040 |
Why?
| | Gene Expression Profiling | 1 | 2026 | 1792 | 0.040 |
Why?
| | Length of Stay | 1 | 2025 | 1358 | 0.040 |
Why?
| | Magnetic Resonance Imaging, Cine | 1 | 2020 | 214 | 0.030 |
Why?
| | Critical Illness | 1 | 2025 | 908 | 0.030 |
Why?
| | Incretins | 1 | 2018 | 21 | 0.030 |
Why?
| | Renal Elimination | 1 | 2018 | 5 | 0.030 |
Why?
| | Macular Edema | 1 | 2018 | 49 | 0.030 |
Why?
| | Inflammation Mediators | 1 | 2021 | 508 | 0.030 |
Why?
| | Glucagon-Like Peptide-2 Receptor | 1 | 2018 | 16 | 0.030 |
Why?
| | Photography | 1 | 2018 | 120 | 0.030 |
Why?
| | Xanthine Oxidase | 1 | 2018 | 79 | 0.030 |
Why?
| | HSP70 Heat-Shock Proteins | 1 | 2018 | 76 | 0.030 |
Why?
| | Cognitive Dysfunction | 1 | 2024 | 481 | 0.030 |
Why?
| | Diet Therapy | 1 | 2018 | 36 | 0.030 |
Why?
| | Cardiovascular System | 1 | 2019 | 137 | 0.030 |
Why?
| | Renal Dialysis | 1 | 2021 | 461 | 0.030 |
Why?
| | Blood Pressure Monitoring, Ambulatory | 1 | 2017 | 69 | 0.030 |
Why?
| | Lipoproteins, LDL | 1 | 2017 | 119 | 0.030 |
Why?
| | Anti-Obesity Agents | 1 | 2018 | 67 | 0.030 |
Why?
| | Renal Plasma Flow, Effective | 1 | 2016 | 1 | 0.030 |
Why?
| | Blood Urea Nitrogen | 1 | 2016 | 53 | 0.030 |
Why?
| | Thiazolidinediones | 1 | 2018 | 142 | 0.030 |
Why?
| | Aldehyde Reductase | 1 | 2016 | 31 | 0.030 |
Why?
| | Telemedicine | 1 | 2026 | 966 | 0.030 |
Why?
| | Water-Electrolyte Balance | 1 | 2016 | 37 | 0.030 |
Why?
| | Infusions, Intravenous | 1 | 2018 | 432 | 0.030 |
Why?
| | Interleukin-6 | 1 | 2021 | 784 | 0.030 |
Why?
| | Ammonia | 1 | 2016 | 61 | 0.030 |
Why?
| | Tomography, Optical Coherence | 1 | 2018 | 283 | 0.030 |
Why?
| | Age Distribution | 1 | 2017 | 399 | 0.030 |
Why?
| | Sex Distribution | 1 | 2017 | 382 | 0.030 |
Why?
| | Proportional Hazards Models | 1 | 2019 | 1331 | 0.030 |
Why?
| | Collagen | 1 | 2018 | 460 | 0.030 |
Why?
| | Waist Circumference | 1 | 2015 | 142 | 0.030 |
Why?
| | Combined Modality Therapy | 1 | 2018 | 1271 | 0.030 |
Why?
| | Blood Glucose Self-Monitoring | 1 | 2019 | 704 | 0.020 |
Why?
| | Complement Activation | 1 | 2016 | 412 | 0.020 |
Why?
| | Circadian Rhythm | 1 | 2017 | 515 | 0.020 |
Why?
| | Exercise Therapy | 1 | 2018 | 488 | 0.020 |
Why?
| | Heart Ventricles | 1 | 2018 | 762 | 0.020 |
Why?
| | Gene-Environment Interaction | 1 | 2014 | 190 | 0.020 |
Why?
| | Comorbidity | 1 | 2017 | 1665 | 0.020 |
Why?
| | Rats, Sprague-Dawley | 1 | 2017 | 2537 | 0.020 |
Why?
| | Models, Statistical | 1 | 2015 | 669 | 0.020 |
Why?
| | Databases, Factual | 1 | 2017 | 1493 | 0.020 |
Why?
| | Non-alcoholic Fatty Liver Disease | 1 | 2014 | 265 | 0.020 |
Why?
| | Algorithms | 1 | 2015 | 1849 | 0.020 |
Why?
| | Hospitalization | 1 | 2017 | 2475 | 0.020 |
Why?
| | Neoplasms | 1 | 2014 | 2954 | 0.010 |
Why?
|
|
Bjornstad's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|